These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 34446578)

  • 1.
    Klümper N; Ralser DJ; Zarbl R; Schlack K; Schrader AJ; Rehlinghaus M; Hoffmann MJ; Niegisch G; Uhlig A; Trojan L; Steinestel J; Steinestel K; Wirtz RM; Sikic D; Eckstein M; Kristiansen G; Toma M; Hölzel M; Ritter M; Strieth S; Ellinger J; Dietrich D
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34446578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CTLA4 DNA methylation is associated with CTLA-4 expression and predicts response to immunotherapy in head and neck squamous cell carcinoma.
    Hoffmann F; Franzen A; de Vos L; Wuest L; Kulcsár Z; Fietz S; Maas AP; Hollick S; Diop MY; Gabrielpillai J; Vogt T; Kuster P; Zarbl R; Dietrich J; Kristiansen G; Brossart P; Landsberg J; Strieth S; Dietrich D
    Clin Epigenetics; 2023 Jul; 15(1):112. PubMed ID: 37415208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma.
    McGregor BA; Lalani AA; Xie W; Steinharter JA; E Bakouny Z; Martini DJ; Fleischer JH; Abou-Alaiwi S; Nassar A; Nuzzo PV; Kaymakcalan MD; Braun DA; Wei XX; Harshman LC; Bilen MA; Choueiri TK
    Eur J Cancer; 2020 Aug; 135():203-210. PubMed ID: 32599410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive analysis of tumor necrosis factor receptor TNFRSF9 (4-1BB) DNA methylation with regard to molecular and clinicopathological features, immune infiltrates, and response prediction to immunotherapy in melanoma.
    Fröhlich A; Loick S; Bawden EG; Fietz S; Dietrich J; Diekmann E; Saavedra G; Fröhlich H; Niebel D; Sirokay J; Zarbl R; Gielen GH; Kristiansen G; Bootz F; Landsberg J; Dietrich D
    EBioMedicine; 2020 Feb; 52():102647. PubMed ID: 32028068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased expression of adenosine 2A receptors in metastatic renal cell carcinoma is associated with poorer response to anti-vascular endothelial growth factor agents and anti-PD-1/Anti-CTLA4 antibodies and shorter survival.
    Kamai T; Kijima T; Tsuzuki T; Nukui A; Abe H; Arai K; Yoshida KI
    Cancer Immunol Immunother; 2021 Jul; 70(7):2009-2021. PubMed ID: 33416945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Change in Neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma.
    Lalani AA; Xie W; Martini DJ; Steinharter JA; Norton CK; Krajewski KM; Duquette A; Bossé D; Bellmunt J; Van Allen EM; McGregor BA; Creighton CJ; Harshman LC; Choueiri TK
    J Immunother Cancer; 2018 Jan; 6(1):5. PubMed ID: 29353553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC.
    Ross-Macdonald P; Walsh AM; Chasalow SD; Ammar R; Papillon-Cavanagh S; Szabo PM; Choueiri TK; Sznol M; Wind-Rotolo M
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33658305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CTLA4 methylation predicts response to anti-PD-1 and anti-CTLA-4 immunotherapy in melanoma patients.
    Goltz D; Gevensleben H; Vogt TJ; Dietrich J; Golletz C; Bootz F; Kristiansen G; Landsberg J; Dietrich D
    JCI Insight; 2018 Jul; 3(13):. PubMed ID: 29997292
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Klümper N; Wüst L; Saal J; Ralser DJ; Zarbl R; Jarczyk J; Breyer J; Sikic D; Wullich B; Bolenz C; Roghmann F; Hölzel M; Ritter M; Strieth S; Hartmann A; Erben P; Wirtz RM; Landsberg J; Dietrich D; Eckstein M
    Oncoimmunology; 2023; 12(1):2267744. PubMed ID: 37868689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of JAK3 promoter methylation and mRNA expression in clear cell renal cell carcinoma.
    Long Q; Huang C; Huang J; Meng Q; Cheng Y; Li Y; He L; Chen M; Zhang C; Wang X; Zhu W; Peng J; Shi D; Zheng F; Dong P; Deng W
    J Adv Res; 2022 Sep; 40():153-166. PubMed ID: 36100323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma.
    Labadie BW; Liu P; Bao R; Crist M; Fernandes R; Ferreira L; Graupner S; Poklepovic AS; Duran I; Maleki Vareki S; Balar AV; Luke JJ
    J Transl Med; 2019 Nov; 17(1):386. PubMed ID: 31767020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma.
    Panda A; de Cubas AA; Stein M; Riedlinger G; Kra J; Mayer T; Smith CC; Vincent BG; Serody JS; Beckermann KE; Ganesan S; Bhanot G; Rathmell WK
    JCI Insight; 2018 Aug; 3(16):. PubMed ID: 30135306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase 2 Trial of Talazoparib and Avelumab in Genomically Defined Metastatic Kidney Cancer.
    Kotecha RR; Doshi SD; Knezevic A; Chaim J; Chen Y; Jacobi R; Zucker M; Reznik E; McHugh D; Shah NJ; Feld E; Aggen DH; Rafelson W; Xiao H; Carlo MI; Feldman DR; Lee CH; Motzer RJ; Voss MH
    Eur Urol Oncol; 2024 Aug; 7(4):804-811. PubMed ID: 37945488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A New Signature That Predicts Progression-Free Survival of Clear Cell Renal Cell Carcinoma with Anti-PD-1 Therapy.
    Lin J; Cai Y; Ma Y; Pan J; Wang Z; Zhang J; Liu Y; Zhao Z
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors Modifying the Associations of Single or Combination Programmed Cell Death 1 and Programmed Cell Death Ligand 1 Inhibitor Therapies With Survival Outcomes in Patients With Metastatic Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-analysis.
    Sati N; Boyne DJ; Cheung WY; Cash SB; Arora P
    JAMA Netw Open; 2021 Jan; 4(1):e2034201. PubMed ID: 33496794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma.
    Brown LC; Zhu J; Desai K; Kinsey E; Kao C; Lee YH; Pabla S; Labriola MK; Tran J; Dragnev KH; Tafe LJ; Dayyani F; Gupta RT; McCall S; George DJ; Glenn ST; Nesline MK; George S; Zibelman M; Morrison C; Ornstein MC; Zhang T
    J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36252996
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Klümper N; Ralser DJ; Bawden EG; Landsberg J; Zarbl R; Kristiansen G; Toma M; Ritter M; Hölzel M; Ellinger J; Dietrich D
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32234847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy.
    Büttner FA; Winter S; Stühler V; Rausch S; Hennenlotter J; Füssel S; Zastrow S; Meinhardt M; Toma M; Jerónimo C; Henrique R; Miranda-Gonçalves V; Kröger N; Ribback S; Hartmann A; Agaimy A; Stöhr C; Polifka I; Fend F; Scharpf M; Comperat E; Wasinger G; Moch H; Stenzl A; Gerlinger M; Bedke J; Schwab M; Schaeffeler E
    Genome Med; 2022 Sep; 14(1):105. PubMed ID: 36109798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive Multi-Omics Identification of Interferon-γ Response Characteristics Reveals That RBCK1 Regulates the Immunosuppressive Microenvironment of Renal Cell Carcinoma.
    Xu W; Tao J; Zhu W; Liu W; Anwaier A; Tian X; Su J; Shi G; Huang H; Wei G; Li C; Qu Y; Zhang H; Ye D
    Front Immunol; 2021; 12():734646. PubMed ID: 34795663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular analysis and favorable clinical outcomes in real-world patients with metastatic renal cell carcinoma.
    Donskov F; Pinto CA; Predoiu R; Fox C; Georgsen JB; Skaarup K; Burcu M; Perini R; Steiniche T
    Acta Oncol; 2022 Oct; 61(10):1268-1277. PubMed ID: 36112410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.